Dr. Reddy’s to acquire 8 generics from Teva
HYDERABAD, India and PRINCETON, N.J. — Over the weekend, Dr. Reddy’s Laboratory announced that it would be acquiring a portfolio of abbreviated new drug applications (ANDAs) from Teva. Dr. Reddy’s will pay $350 million in cash at closing.
The eight products, which Teva is divesting to satisfy terms that will allow it to close its acquisition of Allergan’s generics business, consists of complex generic products awaiting approval and some already approved drugs. The acquisition is contingent on the closing of the Teva/Allergan generics transaction.
“This transaction will add strength to our product portfolio, help us be more relevant in our U.S. market and also create new opportunities for growth,” Dr. Reddy’s CEO and co-chairman G.V. Prasad said.
The products Dr. Reddy’s plans to acquire reflect $3.5 billion in combined annual sales, according to IMS Health data for the 12 months ended April 2016.
ANI gets FDA OK for generic Trileptal, launches 5-mg oxycodone
BAUDETTE, Minn. — ANI Pharmaceuticals on Monday announced the approval of one drug and the launch of another. The company announced that it had received FDA approval for its generic Trileptal (oxcarbazepine) tablets.
The drug will be available from ANI in 150-, 300- and 600-mg dosage strengths, and it saw annual sales of $145 million, according to IMS Health. It is indicated as a monotherapy or adjunctive therapy to treat partial seizures in adults and as monotherapy in the treatment of partial seizures among children with epilepsy 4 years of age and older. It can also be used as an adjunctive therapy in children older than 2 years of age with partial seizures. The company said this approval is part of its efforts to re-activate discontinued abbreviated new drug applications that it has acquired in recent years.
ANI on Monday also introduced its 5-mg oxycodone tablets, which IMS Health says saw $7.5 million in trailing 12-month sales. The drug is indicated to manage moderate to severe acute and chronic pain in patients for whom opioid therapy is deemed appropriate.
“We are excited to add our third Schedule II narcotic product to our commercial portfolio,” ANI president and CEO Arthur S. Przybyl said. “This is ANI's sixth new product introduction in the second quarter of 2016.”
PhRMA launches new webpage to highlight biopharma innovation
WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced Monday the latest effort in the organization’s campaign to highlight America’s biopharmaceutical industry — the launch of a new webpage offering resources about promising scientific advances.
The webpage will offer information on scientific advances in the biopharmaceutical industry’s research and development, information about the current pipeline of new medicine, profiles of the people working to research new treatments and a glossary of terms related to medical research and biopharmaceutical development.
To see the webpage and connect with PhRMA, click here.
Loading Post Please Wait...